During the COVID-19 pandemic, nitazoxanide was investigated for its efficacy against the SARS-CoV-2 virus. While early in vitro studies showed promise, clinical trials have yielded mixed results, with some studies indicating marginal benefits and others showing no significant impact on disease progression. Thus, while it remains a candidate for further research, it is not recommended as a primary treatment for COVID-19 as of now.
